Showing results (411-420 of 439) with videos related to

Sort By:
Pageof 44
Nature Medicine|January 18, 2024
Safety, efficacy and determinants of response of allogeneic CD19-specific CAR-NK cells in CD19+ B cell tumors: a phase 1/2 trialDavid Marin, Ye Li, Rafet Basar, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|April 5, 2016
Efficacy of Pharmacokinetics-Directed Busulfan, Cyclophosphamide, and Etoposide Conditioning and Autologous Stem Cell Transplantation for Lymphoma: Comparison of a Multicenter Phase II Study and CIBMTR OutcomesChristopher R Flowers, Luciano J Costa, Marcelo C Pasquini, et al.
Nature Genetics|November 13, 2012
The genetic landscape of mutations in Burkitt lymphomaCassandra Love, Zhen Sun, Dereje Jima, et al.
Blood Cancer Discovery|June 10, 2022
Follicular Lymphoma Microenvironment Characteristics Associated with Tumor Cell Mutations and MHC Class II ExpressionGuangchun Han, Qing Deng, Mario L Marques-Piubelli, et al.
Blood Advances|September 13, 2021
Early relapse identifies MCL patients with inferior survival after intensive or less intensive frontline therapyDavid A Bond, Jeffrey M Switchenko, Diego Villa, et al.
American Journal of Hematology|January 3, 2023
Targeting MCL-1 and BCL-2 with polatuzumab vedotin and venetoclax overcomes treatment resistance in R/R non-Hodgkin lymphoma: Results from preclinical models and a Phase Ib studyElisabeth A Lasater, Dhara N Amin, Rajat Bannerji, et al.
American Journal of Hematology|April 3, 2020
Efficacy of venetoclax in high risk relapsed mantle cell lymphoma (MCL) - outcomes and mutation profile from venetoclax resistant MCL patientsShuangtao Zhao, Rashmi Kanagal-Shamanna, Lucy Navsaria, et al.
Blood Advances|December 14, 2022
Impact of diagnosis to treatment interval in patients with newly diagnosed mantle cell lymphomaNarendranath Epperla, Jeffrey Switchenko, Veronika Bachanova, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 24, 2025
Five-Year Outcomes of the POLARIX Study Comparing Pola-R-CHP and R-CHOP in Patients With Diffuse Large B-Cell LymphomaFranck Morschhauser, Gilles Salles, Laurie H Sehn, et al.
The Lancet. Oncology|January 25, 2022
Ibrutinib-rituximab followed by R-HCVAD as frontline treatment for young patients (≤65 years) with mantle cell lymphoma (WINDOW-1): a single-arm, phase 2 trialMichael L Wang, Preetesh Jain, Shuangtao Zhao, et al.
Pageof 44